跳到正文
原文
Medical Xpress·· 2026-10-06精选AI 评分68

研究发现:在研抗癌药 zavondemstat 及 QC6352 的真实靶点或为 DHODH 而非 KDM4

Cancer trial drug may work differently than scientists believed, raising concerns for clinical research

AI 导读

一项发表在 Nature Chemical Biology 的研究指出,正在临床试验中用于结直肠癌、胰腺癌和前列腺癌的候选药物 zavondemstat 及相关研究化合物 QC6352,其主要作用机制并非靶向原本假定的 KDM4,而是通过抑制 DHODH 酶发挥作用。

推荐理由

该研究揭示在研药物 zavondemstat 及 QC6352 实际主要靶向 DHODH 而非 KDM4,为解读此类化合物的机制与后续试验设计提供关键背景。

正文 · 原文
cancer cells
Credit: Pixabay/CC0 Public Domain

A cancer drug currently being tested in patients may have entered clinical trials based on an incorrect understanding of how it works, according to a new study led by the University of Sydney in collaboration with Goethe University, Oxford University and the Institute of Cancer Research, London.

Published in Nature Chemical Biology, the study found that the experimental drug zavondemstat and a closely related research compound, QC6352—developed to treat cancers such as colorectal, pancreatic and prostate cancer—do not primarily target KDM4, a family of proteins that can help cancer cells grow and spread when overactive. Instead, both compounds largely work by blocking DHODH, an enzyme cancer cells rely on to produce the molecules needed for rapid growth.

Lead author Professor Lenka Munoz from the University of Sydney School of Medical Sciences and Charles Perkins Center said, "We can think of DHODH as a machine producing bricks needed to build new DNA. If you switch off the machine, the cell starts running out of bricks and can no longer efficiently copy its DNA and keep dividing."

These findings could affect the interpretation of previous studies around the world that used the research compound (QC6352) to investigate the biology of the cancer protein and may have implications for the ongoing clinical development of zavondemstat.

The discovery emerged from research investigating whether zavondemstat and QC6352 could be repurposed for glioblastoma, the most common and aggressive form of brain cancer.

"We tested these compounds to investigate whether they could potentially be repurposed for glioblastoma treatment," Munoz said. "When we tested other KDM4 inhibitors, we found they did not reproduce the anticancer effects observed with QC6352.

"If blocking KDM4 was driving those effects, we would have expected the other inhibitors to behave similarly. Instead, the results suggested QC6352 was acting through a different mechanism."

Using patient-derived glioblastoma stem cells, tumor models and a series of genetic, mechanistic and molecular experiments, the researchers traced the compounds' effects to DHODH rather than KDM4.

"Researchers around the world have used QC6352 as a leading tool to study KDM4 biology, while the related drug zavondemstat progressed into clinical trials based on the same understanding," Munoz said. "Our study found much of the anticancer activity of these compounds is driven by blocking DHODH rather than KDM4."

Study highlights broader issue facing cancer drug development

Munoz said the findings highlight a broader challenge in cancer drug development.

"Getting a drug's mechanism wrong can lead to poorly designed clinical trials, inappropriate patient selection and years of research focused on the wrong biological target," she said.

"There are well-known examples of cancer drugs advancing through large clinical trials before researchers realized they were not working through the mechanism originally proposed.

"Our study shows this is not just a historical problem but one still happening today. Greater rigor is needed to ensure we understand exactly how potential treatments work before they move into clinical testing.

"Establishing a drug's true mechanism early can protect patients, prevent wasted research effort and help ensure what limited funding we have is directed toward genuinely promising treatments."

The findings also point to DHODH inhibition as a potential new avenue for glioblastoma treatment. Several drugs targeting DHODH are already being investigated for other cancers, raising the possibility they could eventually be tested in patients with brain cancer.

Beyond identifying the drug's true target, the researchers developed new compounds that inhibit KDM4 without affecting DHODH, which could help scientists study the role of KDM4 more accurately in future cancer research.

Publication details

DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells, Nature Chemical Biology (2026). DOI: 10.1038/s41589-026-02306-x

Journal information: Nature Chemical Biology

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Cancer trial drug may work differently than scientists believed, raising concerns for clinical research (2026, October 6) retrieved 6 October 2026 from https://medicalxpress.com/news/2026-10-cancer-trial-drug-differently-scientists.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com